Replimune Group is under investigation by Pomerantz LLP for potential securities fraud following the FDA's rejection of its Biologics License Application for a melanoma treatment. The FDA disagreed with the company over the sufficiency of data supporting the drug RP1 combined with nivolumab. This news caused Replimune's stock to drop sharply by 64.29%, closing at $1.70 per share. The investigation aims to determine if the company or its officers engaged in unlawful business practices, with affected investors encouraged to join a class action lawsuit.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Citigroup downgraded Apollo Global Management's stock from Buy to Reduce due to concerns over a potential economic slowdown and a sharp drop in U.S. private credit lending. Apollo's shares are trading well below their 52-week high, reflecting caution...
Conagra Brands reported its Q2 earnings with an EPS of $0.47, slightly beating estimates but down from last year. Revenue missed expectations at $2.88 billion, and the company announced a loss and a significant dividend cut as part of a new conservat...
